Africa Asia Middle East عربي Français Português Subscribe IRIN Site Map
PlusNews
Global HIV/AIDS news and analysis
Advanced search
 Monday 22 September 2008
 
Home 
Africa 
Blog 
Weekly reports 
In-Depth reports 
Country profiles 
Fact files 
Events 
Jobs 
Most read 
Really Simple Syndication Feeds 
About PlusNews 
Donors 
Contact PlusNews 
 
Print report
SOUTH AFRICA: ARV and TB drugs taken together halve deaths


Photo: Georgina Cranston/IRIN
Changing treatment protocols for co-infected patients could save lives
JOHANNESBURG, 19 September 2008 (PlusNews) - Combining antiretroviral (ARV) therapy with treatment for tuberculosis (TB) could more than halve the current mortality rate among patients co-infected with HIV and TB, saving an estimated 10,000 lives a year in South Africa.

These are the findings of a clinical trial by the Centre for the AIDS Programme of Research in South Africa (CAPRISA) in Durban, which compared mortality rates in three groups of co-infected patients who began ARV treatment at different stages of their TB therapy.

One group started taking ARVs in the first two months of TB treatment; a second group started taking them soon after completing their first two months on TB drugs; and a third group of patients did not begin ARV treatment until they had completed their six- to eight-month course of TB medication.

This third arm of the trial reflects the current practice in South Africa, which is based on the theory that taking ARV and TB drugs simultaneously can result in harmful interactions and reduce the effectiveness of both types of medications.

It is a theory that has never before been clinically tested. A recommendation by the World Health Organisation (WHO) that only patients with a CD4 count (which measures the strength of the immune system) below 50 should take TB and ARV treatment together, is based on doctors' observations.

A safety monitoring committee recommended closing down the third arm of the CAPRISA trial earlier this month, after the death rate in that group was found to be 55 percent higher than in the two groups on integrated ARV and TB treatment.

The study found that even patients with CD4 counts of between 200 and 500 were more likely to die if ARV treatment was delayed until they had finished their TB therapy. The American Association for Clinical Chemistry puts the normal CD4 count in adults from 500 to 1,500 cells per cubic millimetre of blood.

''We should urgently evaluate our practice''
Reacting to the findings, Dr Francois Venter, head of the Southern African HIV Clinicians Society noted that few clinicians would be surprised by the results for patients with CD4 counts below 200.

"However, the striking mortality difference above 200 will force us to re-look at the way we treat these patients, which has traditionally been to complete the full TB course before starting antiretrovirals," he said. "Using this approach means that many patients will die, and we should urgently evaluate our practice."

According to the WHO, up to 30 percent of co-infected patients in sub-Saharan Africa die before finishing their TB treatment; in South Africa, more than 60 percent of patients with TB also have HIV.

Results from the two remaining arms of the trial regarding the optimal time to start integrating ARV treatment with TB treatment are not expected until 2010. In the meantime, trial researchers said the findings "provide strong evidence for the integration of TB and AIDS care and treatment".

In a statement released this week, they recommended that all newly diagnosed TB patients be offered an HIV test, and that those who test positive and have CD4 counts below 500 be given ARV treatment in addition to TB treatment. In South Africa only patients with a CD4 count below 200 qualify for ARV treatment.

HIV specialists have urged the health department to revise its treatment guidelines in response to evidence that patients who start ARV treatment earlier respond better to treatment and are less likely to develop AIDS-related illnesses like TB, but the department has yet to do so.

Venter noted that the CAPRISA study answered one of the most important questions in the field of HIV. "We need to act on this data quickly," he said.

ks/he


Theme(s): (IRIN) Care/Treatment - PlusNews, (IRIN) HIV/AIDS (PlusNews)

[ENDS]

[This report does not necessarily reflect the views of the United Nations]
Print report
Countries
FREE Subscriptions
Your e-mail address:


Submit your request
 More on South Africa
19/Sep/2008
GLOBAL: IRIN/PlusNews Weekly Issue 405, 19 September 2008
12/Sep/2008
GLOBAL: Economic slowdown to push 100m into poverty
09/Sep/2008
SOUTH AFRICA: Questions about new prevalence survey
29/Aug/2008
GLOBAL: Food wasted is water lost
27/Aug/2008
SOUTH AFRICA: The less shiny side of platinum
 More on Care/Treatment - PlusNews
18/Sep/2008
SWAZILAND: Treatment programme woes
16/Sep/2008
NAMIBIA: Strategies to keep patients on ARVs
10/Sep/2008
UGANDA: Genocide by Denial
04/Sep/2008
ZIMBABWE: Union provides free ARVs to journalists
03/Sep/2008
UGANDA: Drug supply chain problems trigger shortages
Share:
Back | Home page

Services:  Africa | Asia | Middle East | Radio | Film & TV | Photo | E-mail subscription
Feedback · E-mail Webmaster · IRIN Terms & Conditions · Really Simple Syndication News Feeds · About PlusNews · Bookmark PlusNews · Donors

Copyright © IRIN 2008
This material comes to you via IRIN, the humanitarian news and analysis service of the UN Office for the Coordination of Humanitarian Affairs. The opinions expressed do not necessarily reflect those of the United Nations or its Member States. Republication is subject to terms and conditions as set out in the IRIN copyright page.